JP2009529538A - サーチュイン活性化剤を用いる眼処置 - Google Patents

サーチュイン活性化剤を用いる眼処置 Download PDF

Info

Publication number
JP2009529538A
JP2009529538A JP2008558515A JP2008558515A JP2009529538A JP 2009529538 A JP2009529538 A JP 2009529538A JP 2008558515 A JP2008558515 A JP 2008558515A JP 2008558515 A JP2008558515 A JP 2008558515A JP 2009529538 A JP2009529538 A JP 2009529538A
Authority
JP
Japan
Prior art keywords
implant
eye
sirtuin activator
sirtuin
resveratrol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008558515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529538A5 (enExample
Inventor
ジョン・イー・ドネロ
ロン・ヤン
エリザベス・ウォルド・ムッシー
ファビアン・ジ・シュウェゴフェ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2009529538A publication Critical patent/JP2009529538A/ja
Publication of JP2009529538A5 publication Critical patent/JP2009529538A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
JP2008558515A 2006-03-08 2007-03-07 サーチュイン活性化剤を用いる眼処置 Pending JP2009529538A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/371,117 US20070212395A1 (en) 2006-03-08 2006-03-08 Ocular therapy using sirtuin-activating agents
PCT/US2007/063454 WO2007103960A1 (en) 2006-03-08 2007-03-07 Ocular therapy using sirtuin-activating agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013185851A Division JP2014028822A (ja) 2006-03-08 2013-09-09 サーチュイン活性化剤を用いる眼処置

Publications (2)

Publication Number Publication Date
JP2009529538A true JP2009529538A (ja) 2009-08-20
JP2009529538A5 JP2009529538A5 (enExample) 2010-04-22

Family

ID=38230138

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008558515A Pending JP2009529538A (ja) 2006-03-08 2007-03-07 サーチュイン活性化剤を用いる眼処置
JP2013185851A Pending JP2014028822A (ja) 2006-03-08 2013-09-09 サーチュイン活性化剤を用いる眼処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013185851A Pending JP2014028822A (ja) 2006-03-08 2013-09-09 サーチュイン活性化剤を用いる眼処置

Country Status (7)

Country Link
US (1) US20070212395A1 (enExample)
EP (1) EP1991205A1 (enExample)
JP (2) JP2009529538A (enExample)
AU (1) AU2007223057B2 (enExample)
BR (1) BRPI0708622A2 (enExample)
CA (1) CA2643903C (enExample)
WO (1) WO2007103960A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140048212A (ko) 2011-06-29 2014-04-23 가부시키가이샤 롯데 눈 피로 억제 조성물 및 그것을 함유하는 음식품
JP2015107924A (ja) * 2013-12-04 2015-06-11 ライオン株式会社 涙液分泌促進剤、眼精疲労予防・改善剤及び眼の調節力低下予防・改善剤
JP2023507783A (ja) * 2019-12-19 2023-02-27 ペンダント バイオサイエンシズ インコーポレイテッド 架橋ｐｌａ系共重合体

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20090169585A1 (en) * 2003-10-23 2009-07-02 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20060062690A1 (en) * 2004-08-17 2006-03-23 Polymer Technology Systems, Inc. Apparatus and method of manufacturing bodily fluid test strip
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
WO2007146234A2 (en) * 2006-06-09 2007-12-21 Merrion Research Ii Limited Solid oral dosage form containing an enhancer
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
JP2010540444A (ja) * 2007-09-20 2010-12-24 レスベラトロル パートナーズ， エルエルシー 遺伝子産物の濃縮または活性を調節するためのレスベラトロールを含む組成物
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP5591226B2 (ja) 2008-05-12 2014-09-17 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション 眼内薬物送達装置および関連する方法
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
JP5937004B2 (ja) 2009-05-18 2016-06-22 ドーズ メディカル コーポレーションＤｏｓｅ Ｍｅｄｉｃａｌ Ｃｏｒｐｏｒａｔｉｏｎ 薬剤溶出眼内インプラント
EP2470157A1 (en) * 2009-08-24 2012-07-04 The Board of Governors for Higher Education, State of Rhode Island and Providence Plantations Hot-melt extruded compositions containing plant-derived phenolic materials and processes for the preparation thereof
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
AU2011341637A1 (en) * 2010-12-15 2013-06-20 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
WO2013058838A2 (en) 2011-06-10 2013-04-25 Wong Vernon G Conveniently injectable or implantable sustained-release antioxidant formulations for therapies of ocular maladies or cancer
ES2428665B1 (es) * 2012-05-04 2014-10-01 Universidad De Valladolid Composición para su uso en el tratamiento y/o prevención de la inflamación, el estrés oxidativo y la neovascularización ocular
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
WO2014165308A2 (en) 2013-04-01 2014-10-09 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
EP4046628A1 (en) 2013-10-31 2022-08-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
AU2015266850B2 (en) 2014-05-29 2019-12-05 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
TWI658828B (zh) * 2014-10-31 2019-05-11 中國醫藥大學 用於舒緩及減輕近視之醫藥組合物及其製備方法與用途
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
HUE057052T2 (hu) 2016-02-18 2022-04-28 Invirsa Inc 5'-adenozin-difoszfát-ribóz (ADPR) gyógyászati alkalmazása
CA3022830A1 (en) 2016-04-20 2017-10-26 Harold Alexander Heitzmann Bioresorbable ocular drug delivery device
WO2019191026A2 (en) 2018-03-27 2019-10-03 Invirsa, Inc. Methods for the use of 5'-adenosine diphosphate ribose (adpr)
WO2020115765A1 (en) 2018-12-05 2020-06-11 Celagenex Research (India) Pvt. Ltd. Novel synergistic composition comprising sirt1 and ampk activators for treating metabolic syndrome
CN114917209B (zh) * 2022-05-23 2024-01-23 广西大学 白皮杉醇在抗弓形虫感染的应用
WO2024180472A1 (en) * 2023-02-28 2024-09-06 Alcon Inc. Ocular inserts
USD1137672S1 (en) 2024-08-27 2026-07-28 Glaukos Corporation Drug eluting ocular implant

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506450A (ja) * 1995-06-02 1999-06-08 オキュレックス ファーマシューティカルズ，インコーポレイティド 親水性及び疎水性薬剤の組合せによる薬剤の制御放出のための改良処方物
WO2005077176A1 (en) * 2004-02-11 2005-08-25 The Trustees Of Columbia University In The City Of New York Anthocyanin compounds and methods of use thereof
WO2005107707A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005107727A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Steroid intraocular implants having an extended sustained release for a period of greater than two months
WO2005107708A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
WO2005110380A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies
WO2005110368A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular implants of alpha-2 adrenergic receptor agonists and methods for improving vision
WO2005110436A2 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Macromolecule-containing sustained release intraocular implants and related methods
WO2005110424A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Biodegradable intraocular implants containing prostamides
WO2006001982A2 (en) * 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963025A (en) * 1974-09-16 1976-06-15 Alza Corporation Ocular drug delivery device
US4521210A (en) * 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
WO1995003009A1 (en) * 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
AUPO427196A0 (en) * 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
EP1003569B1 (en) * 1997-08-11 2004-10-20 Allergan, Inc. Sterile bioerodible implant device containing retinoid with improved biocompatability and method of manufacture
US6331313B1 (en) * 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
AUPQ496500A0 (en) * 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6699493B2 (en) * 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US20050096256A1 (en) * 2003-07-01 2005-05-05 President And Fellows Of Harvard College Compositions for manipulating the lifespan and stress response of cells and organisms
US20070014833A1 (en) * 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
CA2609549A1 (en) * 2005-05-25 2006-11-30 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11506450A (ja) * 1995-06-02 1999-06-08 オキュレックス ファーマシューティカルズ，インコーポレイティド 親水性及び疎水性薬剤の組合せによる薬剤の制御放出のための改良処方物
WO2005077176A1 (en) * 2004-02-11 2005-08-25 The Trustees Of Columbia University In The City Of New York Anthocyanin compounds and methods of use thereof
WO2005107707A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing
WO2005107727A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Steroid intraocular implants having an extended sustained release for a period of greater than two months
WO2005107708A1 (en) * 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
WO2005110380A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies
WO2005110368A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Intraocular implants of alpha-2 adrenergic receptor agonists and methods for improving vision
WO2005110436A2 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Macromolecule-containing sustained release intraocular implants and related methods
WO2005110424A1 (en) * 2004-04-30 2005-11-24 Allergan, Inc. Biodegradable intraocular implants containing prostamides
WO2006001982A2 (en) * 2004-06-04 2006-01-05 Washington University Methods and compositions for treating neuropathies

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140048212A (ko) 2011-06-29 2014-04-23 가부시키가이샤 롯데 눈 피로 억제 조성물 및 그것을 함유하는 음식품
JP2015107924A (ja) * 2013-12-04 2015-06-11 ライオン株式会社 涙液分泌促進剤、眼精疲労予防・改善剤及び眼の調節力低下予防・改善剤
JP2023507783A (ja) * 2019-12-19 2023-02-27 ペンダント バイオサイエンシズ インコーポレイテッド 架橋ｐｌａ系共重合体

Also Published As

Publication number Publication date
CA2643903A1 (en) 2007-09-13
JP2014028822A (ja) 2014-02-13
AU2007223057A1 (en) 2007-09-13
US20070212395A1 (en) 2007-09-13
AU2007223057B2 (en) 2011-07-21
WO2007103960A1 (en) 2007-09-13
EP1991205A1 (en) 2008-11-19
BRPI0708622A2 (pt) 2011-06-07
CA2643903C (en) 2016-06-28

Similar Documents

Publication Publication Date Title
JP2014028822A (ja) サーチュイン活性化剤を用いる眼処置
JP5485314B2 (ja) ２ヶ月を超える期間の長期持続放出を与えるステロイド眼内インプラント
JP5696121B2 (ja) α−２アドレナリン受容体アゴニスト含有生分解性眼内インプラント
JP5826872B2 (ja) 眼内使用のための環状脂質インプラントの製造法
JP5580832B2 (ja) 生分解性α−２アゴニストポリマー性インプラントおよびその治療用途
JP5745208B2 (ja) 後区組織に選択的に浸透するグルココルチコイド誘導体を用いた眼治療
JP2008540552A (ja) 増大した前部クリアランス速度を有するα−２アドレナリン受容体アゴニストを用いる眼科治療
AU2016231616A1 (en) Intraocular sustained release drug delivery systems and methods for treating ocular conditions
JP2007535563A (ja) レチノイド含有徐放性薬剤送達システム、ならびに関連する製造法
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
JP2007535539A (ja) β−アドレナリン受容体拮抗薬を含む持続放出眼内インプラントおよび眼の神経障害の治療方法
TW201143742A (en) Intracameral devices for sustained delivery
JP2007535564A (ja) 抗興奮毒性剤持続放出眼内インプラントおよび関連方法
Gavini et al. Biodegradable microspheres as intravitreal delivery systems for prolonged drug release. What is their eminence in the nanoparticle era?
AU2011239238B2 (en) Ocular therapy using sirtuin-activating agents
JP7855531B2 (ja) 生分解性組成物およびインプラント
Rajput et al. Processed Excipients in Ocular Drug Delivery
Bhanu Malhotra et al. Ocular drug delivery systems.
HK40092515B (en) Biodegradable compositions and implants
HK40092515A (en) Biodegradable compositions and implants
Mittal et al. Recent Advancement in Ocular Drug Delivery System: A Systematic

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100304

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120814

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121114

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121121

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121214

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130115

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130909